World Journal of Surgery

, Volume 31, Issue 2, pp 337–342 | Cite as

Pancreatoduodenectomy for Distal Cholangiocarcinoma: Prognostic Impact of Lymph Node Metastasis

  • Yoshiaki Murakami
  • Kenichiro Uemura
  • Yasuo Hayashidani
  • Takeshi Sudo
  • Hiroki Ohge
  • Taijiro Sueda
Article
First Online:

Abstract

Background

The aim of this study was to identify useful prognostic factors in patients undergoing pancreatoduodenectomy for distal cholangiocarcinoma.

Methods

The records of 36 patients with distal cholangiocarcinoma undergoing pancreatoduodenectomy were retrospectively reviewed. Potential clinicopathological prognostic factors that may affect survival were examined by univariate and multivariate analysis.

Results

There was no mortality. Overall survival rates were 75%, 54%, and 50% for 1, 3 and 5 years, respectively (median survival time, 26 months). Univariate analysis found that age (≧ 65 years), pancreatic invasion, duodenal invasion, lymph node metastasis, perineural invasion and a positive surgical margin were significant predictors of poor prognosis (P < 0.05). Furthermore, lymph node metastasis was found to be a significant independent predictor of poor prognosis by multivariate analysis (P = 0.043). Moreover, there were significant differences in the 5-year survival between patients with 2 or less involved lymph nodes and those with 3 or more positive nodes (P < 0.001). There were no 2-year survivors of the group of patients with 3 or more positive nodes.

Conclusions

These results suggest that the presence and number of lymph nodes exhibiting metastatic disease might be useful in predicting the postsurgical outcome in patients undergoing pancreatoduodenectomy for distal cholangiocarcinoma.

Keywords

Bile Duct Cholangiocarcinoma Positive Node Perineural Invasion Biliary Tract Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–473PubMedCrossRefGoogle Scholar
  2. 2.
    Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 1998;34:977–986PubMedCrossRefGoogle Scholar
  3. 3.
    Yee K, Sheppard BC, Domreis J, et al. Cancers of the gallbladder and biliary ducts. Oncology (Williston Park) 2002;16:939–957Google Scholar
  4. 4.
    Park SW, Park YS, Chung JB, et al. Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroenterology 2004;51:1612–1618PubMedGoogle Scholar
  5. 5.
    Yoshida T, Matsumoto T, Sasaki A, et al. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002;137:69–73PubMedCrossRefGoogle Scholar
  6. 6.
    Sasaki R, Takahashi M, Funato O, et al. Prognostic significance of lymph node involvement in middle and distal bile duct cancer. Surgery 2001;129:677–683PubMedCrossRefGoogle Scholar
  7. 7.
    Suzuki M, Unno M, Oikawa M, et al. Surgical treatment and postoperative outcomes for middle and lower bile duct carcinoma in Japan: experience of a single institute. Hepatogastroenterology 2000;47:650–657PubMedGoogle Scholar
  8. 8.
    Kayahara M, Nagakawa T, Ohta T, et al. Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg 1999;229:76–83PubMedCrossRefGoogle Scholar
  9. 9.
    Zerbi A, Balzano G, Leone BE, et al. Clinical presentation, diagnosis and survival of resected distal bile duct cancer. Dig Surg 1998;15:410–416PubMedCrossRefGoogle Scholar
  10. 10.
    Wade TP, Prasad CN, Virgo KS, et al. Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987–1991. J Surg Oncol 1997;64:242–245PubMedCrossRefGoogle Scholar
  11. 11.
    Fong Y, Blumgart LH, Lin E, et al. Outcome of treatment for distal bile duct cancer. Br J Surg 1996;83:1712–1715PubMedGoogle Scholar
  12. 12.
    Nagorney DM, Donohue JH, Farnell MB, et al. Outcomes after curative resections of cholangiocarcinoma. Arch Surg 1993;128:871–877PubMedGoogle Scholar
  13. 13.
    Sakamoto Y, Kosuge T, Shimada K, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery 2005;137:396–402PubMedCrossRefGoogle Scholar
  14. 14.
    Reding R, Buard JL, Lebeau G, et al. Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded). Results of the French Surgical Association Survey. Ann Surg 1991;213:236–241PubMedCrossRefGoogle Scholar
  15. 15.
    Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995;130:270–276PubMedGoogle Scholar
  16. 16.
    Schoenthaler R, Phillips TL, Castro J, et al. Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg 1994;219:267–274PubMedCrossRefGoogle Scholar
  17. 17.
    Guthrie CM, Haddock G, De Beaux AC, et al. Changing trends in the management of extrahepatic cholangiocarcinoma. Br J Surg 1993;80:1434–1439PubMedGoogle Scholar
  18. 18.
    Japanese Society of Biliary Surgery. General rules for surgical and pathological studies on cancer of biliary tract, 4th edition. Tokyo, Kanehara, 1997Google Scholar
  19. 19.
    Inoue K, Makuuchi M, Takayama T, et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000;127:498–505PubMedGoogle Scholar
  20. 20.
    Ebata T, Nagino M, Kamiya J, et al. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 2003;238:720–727PubMedCrossRefGoogle Scholar
  21. 21.
    de Aretxabala X, Roa I, Burgos L, et al. Gallbladder cancer: an analysis of a series of 139 patients with invasion restricted to the subserosal layer. J Gastrointest Surg 2006;10:186–192PubMedCrossRefGoogle Scholar
  22. 22.
    Sobin LH, Wittekind C, editors. Internatinal Union Against Cancer (UICC): TNM Classification of Malignant Tumors, 6th edition. New York: Wiley-Liss, 2002Google Scholar
  23. 23.
    Nakagawa T, Kamiyama T, Kurauchi N, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 2005;29:728–733PubMedCrossRefGoogle Scholar
  24. 24.
    Hong SM, Cho H, Lee OJ, et al. The number of metastatic lymph nodes in extrahepatic bile duct carcinoma as a prognostic factor. Am J Surg Pathol 2005;29:1177–1183PubMedCrossRefGoogle Scholar
  25. 25.
    Roder JD, Schneider PM, Stein HJ, et al. Number of lymph node metastases is significantly associated with survival in patients with radically resected carcinoma of the ampulla of Vater. Br J Surg 1995;82:1693–1696PubMedGoogle Scholar
  26. 26.
    Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005;103:111–118PubMedCrossRefGoogle Scholar
  27. 27.
    Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001;12:183–186PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2006

Authors and Affiliations

  • Yoshiaki Murakami
    • 1
  • Kenichiro Uemura
    • 1
  • Yasuo Hayashidani
    • 1
  • Takeshi Sudo
    • 1
  • Hiroki Ohge
    • 1
  • Taijiro Sueda
    • 1
  1. 1.Department of Surgery, Division of Clinical Medical Science, Graduate School of Biomedical SciencesHiroshima UniversityMinami-kuJapan

Personalised recommendations